X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DIVIS LABORATORIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DIVIS LABORATORIES GSK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 58.9 35.3 166.6% View Chart
P/BV x 11.0 6.9 160.2% View Chart
Dividend Yield % 2.6 0.7 400.9%  

Financials

 GSK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
GSK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,7601,142 241.7%   
Low Rs2,040533 382.7%   
Sales per share (Unadj.) Rs339.0146.6 231.3%  
Earnings per share (Unadj.) Rs41.433.0 125.4%  
Cash flow per share (Unadj.) Rs45.938.4 119.5%  
Dividends per share (Unadj.) Rs35.0010.00 350.0%  
Dividend yield (eoy) %1.51.2 122.1%  
Book value per share (Unadj.) Rs242.9222.8 109.0%  
Shares outstanding (eoy) m84.70265.47 31.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.15.7 123.9%   
Avg P/E ratio x57.925.3 228.6%  
P/CF ratio (eoy) x52.321.8 239.8%  
Price / Book Value ratio x9.93.8 262.9%  
Dividend payout %84.530.3 279.2%   
Avg Mkt Cap Rs m203,280222,318 91.4%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m5,2344,561 114.8%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m28,71538,915 73.8%  
Other income Rs m5451,134 48.1%   
Total revenues Rs m29,26040,049 73.1%   
Gross profit Rs m5,05912,617 40.1%  
Depreciation Rs m3801,425 26.7%   
Interest Rs m213 15.0%   
Profit before tax Rs m5,22212,313 42.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8923,543 53.4%   
Profit after tax Rs m3,5088,770 40.0%  
Gross profit margin %17.632.4 54.3%  
Effective tax rate %36.228.8 125.9%   
Net profit margin %12.222.5 54.2%  
BALANCE SHEET DATA
Current assets Rs m21,81545,351 48.1%   
Current liabilities Rs m15,9996,507 245.9%   
Net working cap to sales %20.399.8 20.3%  
Current ratio x1.47.0 19.6%  
Inventory Days Days64127 50.2%  
Debtors Days Days1995 19.6%  
Net fixed assets Rs m12,47521,160 59.0%   
Share capital Rs m847531 159.5%   
"Free" reserves Rs m19,72658,625 33.6%   
Net worth Rs m20,57359,156 34.8%   
Long term debt Rs m60-   
Total assets Rs m39,47567,832 58.2%  
Interest coverage x2,612.0926.8 281.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 126.8%   
Return on assets %8.912.9 68.7%  
Return on equity %17.114.8 115.0%  
Return on capital %26.220.8 126.0%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m56432,359 1.7%   
Fx outflow Rs m7,4299,042 82.2%   
Net fx Rs m-6,86523,317 -29.4%   
CASH FLOW
From Operations Rs m4,7287,759 60.9%  
From Investments Rs m-1,042-4,783 21.8%  
From Financial Activity Rs m-3,066-3,142 97.6%  
Net Cashflow Rs m620-166 -373.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.8 86.4%  
FIIs % 23.8 19.0 125.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   102,036 31,796 320.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 15, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS